Reportlinker Adds Prostate Cancer - BRIC Drug Forecasts and Treatment Analysis to 2020

Dec 09, 2010, 12:21 ET from Reportlinker

NEW YORK, Dec. 9, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Prostate Cancer - BRIC Drug Forecasts and Treatment Analysis to 2020

http://www.reportlinker.com/p0336634/Prostate-Cancer---BRIC-Drug-Forecasts-and-Treatment-Analysis-to-2020.html

Prostate Cancer - BRIC Drug Forecasts and Treatment Analysis to 2020

Summary

GlobalData's pharmaceutical report, "Prostate Cancer - Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020" is an essential source of information and analysis on the prostate cancer therapeutics market in the emerging BRIC countries. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the prostate cancer therapeutics market in Brazil, Russia, India and China. It analyzes the treatment usage patterns in the BRIC prostate cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the BRIC prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

- An overview of prostate cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized prostate cancer therapeutics market revenue, the annual cost of therapy and treatment usage patterns (for hormone therapy and hormone resistant or refractory therapy) for the BRIC countries from 2001 to 2009, forecast for 11 years to 2020.

- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.

- Competitor assessment.

- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals and life cycle management activities.

- Analysis of unmet need in the market and target product profiles including the opportunities for targeted products.

- Technology trends analytic framework to assess strength of pipeline.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.

- An overview of the most promising drugs, including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.

- Analysis of the current and future market competition in the global prostate cancer therapeutics market. Company profiles including a business description, a financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.

- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A) analysis, which includes M&A deals by size and geography.

- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

- Develop business strategies and perform superior market quantification analysis by

- Understanding the trends shaping and driving the Japanese prostate cancer therapeutics market.

- Understanding the treatment preferences of physicians according to disease state and across treatment flow.

- Assessing market sizing, forecasts and quantified growth opportunities in the BRIC prostate cancer therapeutics market up to 2020.

- Quantifying the patient population in the BRIC countries to better design product pricing and launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

- Performing benchmarking analysis and growth opportunities against currently marketed products.

- Identifying market entry points based on safety, efficacy and pricing parameters.

- Assessing competitiveness of products in market by understanding the strength and weakness of the current competition.

- Develop and design your in-licensing and out-licensing strategies by

- Taking a comprehensive look of at the disease pipeline and identifying the most promising paradigm shifting products.

- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

1 Table of contents 3

1.1 List of Tables 7

1.2 List of Figures 8

2 Disease Overview 11

2.1 Overview 11

2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 11

2.1.2 Jewett-Whitmore system 12

2.2 Epidemiology 12

2.3 Etiology 13

2.4 Symptoms 13

2.4.1 Localized or Locally Advanced Prostate Cancer 13

2.4.2 Metastatic Prostate Cancer 13

2.5 Diagnosis 14

2.5.1 Digital Rectal Examination 14

2.5.2 Prostate Specific Antigen Test 14

2.5.3 Transrectal Ultrasound 15

2.5.4 Prostate Biopsy 15

2.6 Pathology 15

2.6.1 Grading 15

2.7 Treatment 16

2.7.1 Watchful Waiting 16

2.7.2 Radiation therapy 16

2.7.3 Surgery 17

2.7.4 Hormone therapy 17

2.7.5 Chemotherapy Options 18

2.7.6 Other Treatments Being Studied 19

2.8 Treatment Guidelines 20

3 Market Characterization 21

3.1 BRIC (Brazil, Russia, India and China) 21

3.1.1 Market Size 21

3.1.2 Forecasts 26

3.2 Brazil 31

3.2.1 Market Size 31

3.2.2 Drivers and Restraints 36

3.2.3 Impact on the Market 37

3.2.4 Forecasts 38

3.2.5 Future Impact 43

3.3 Russia 44

3.3.1 Market Size 44

3.3.2 Drivers and Restraints 49

3.3.3 Impact on the Market 50

3.3.4 Forecasts 51

3.3.5 Future Impact 56

3.4 India 57

3.4.1 Market Size (2001-2009) 57

3.4.2 Drivers and Restraints 62

3.4.3 Impact on the Market 63

3.4.4 Forecasts (2010-2020) 64

3.4.5 Future Impact 69

3.5 China 70

3.5.1 Market Size (2001-2009) 70

3.5.2 Drivers and Restraints 75

3.5.3 Impact on the Market 76

3.5.4 Forecasts (2010-2020) 77

3.5.5 Future Impact 82

3.6 Key Takeaway 82

4 Competitor Assessment 83

4.1 Strategic Competitor Assessment 83

4.1.1 Overview 83

4.1.2 Benchmarking 83

4.1.3 Current Competitor Assessment 87

4.2 Product Profiles 89

4.2.1 Taxotere (docetaxel) 90

4.2.2 Casodex (Bicalutamide) 93

4.2.3 Zoladex (Goserelin) 97

4.2.4 Eligard (leuprolide acetate) 99

4.2.5 Lupron (Leuprolide acetate) 102

4.2.6 Firmagon (degarelix) 106

4.2.7 Novantrone (Mitoxantrone hydrochloride) 108

4.2.8 Emcyt (estramustine) 110

4.2.9 Trelstar (triptorelin) 111

4.2.10 Eulexin 112

4.2.11 Delestrogen 114

4.2.12 Gynodiol 115

4.2.13 Estrace tablet 116

4.2.14 Tace 117

4.2.15 Nilandrone 118

4.2.16 Premarin 119

5 Pipeline Assessment 120

5.1 Overview 120

5.2 Pipeline Analysis by Phase of Development 121

5.3 Pipeline by Mechanism of Action 122

5.4 Strategic Pipeline Assessment 123

5.4.1 Technology Trends Analytical Framework 123

5.5 Trends in Prostate Cancer Pipeline 124

5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 124

5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 124

5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 124

5.6 Partners in Research and Development 125

5.6.1 Licensing Agreements by Phase of Development 125

5.6.2 Licensing Agreements by Geography 128

5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 128

5.7 Most Promising Drugs' Profiles 129

5.7.1 Provenge (sipuleucel-T) 131

5.7.2 Jevtana (cabazitaxel) 132

5.7.3 Aflibercept (VEGF Trap) 133

5.7.4 Ipilimumab 135

5.7.5 Abiraterone Acetate (CB7630) 136

5.7.6 Zibotentan (ZD4054) 138

5.7.7 Sprycel (dasatinib) 139

5.7.8 MDV3100 141

5.8 Prostate Cancer Pipeline – Pre-clinical Phase 143

5.9 Prostate Cancer Pipeline – Phase I 145

5.10 Prostate Cancer Pipeline – Phase II 147

5.11 Prostate Cancer Pipeline – Phase III 154

5.12 Key Takeaway 156

6 Unmet Need and Target Product Profile 157

6.1 Unmet Need 159

6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 159

6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 160

6.2 Opportunity for Target Product 161

6.3 Target Product Profile 163

6.3.1 Ideal Characteristics 163

6.3.2 Target Product Description 164

6.4 Key Takeaway 164

7 Strategic Assessment 165

7.1 Key Events Impacting the Future Market 165

7.2 Market Impact Analysis 166

7.3 Future Market Scenario 166

7.4 Company Analysis 168

7.4.1 Market Leadership 168

7.4.2 Future Players in the Market 168

7.5 Key Takeaway 169

8 Company Profiles 170

8.1 Sanofi-aventis 170

8.1.1 Business Description 170

8.1.2 Financial Overview 172

8.1.3 SWOT Analysis 172

8.1.4 Oncology Focus 177

8.2 Pfizer Inc. 178

8.2.1 Business Description 178

8.2.2 Financial Overview 179

8.2.3 SWOT Analysis 179

8.2.4 Oncology Focus 185

8.3 AstraZeneca 186

8.3.1 Business Description 186

8.3.2 Financial Overview 188

8.3.3 SWOT Analysis 188

8.3.4 Oncology Focus 192

8.4 Bristol-Myers Squibb 194

8.4.1 Business Description 194

8.4.2 Financial Overview 195

8.4.3 SWOT Analysis 195

8.4.4 Oncology Focus 200

8.5 Medivation 202

8.5.1 Business Description 202

8.5.2 SWOT Analysis 203

8.5.3 Oncology Focus 206

8.6 Takeda Pharmaceuticals 206

8.6.1 Business Description 206

8.6.2 SWOT Analysis 206

8.7 Dendreon Corporation 208

8.7.1 Business Description 208

8.7.2 SWOT Analysis 208

8.8 Johnson and Johnson 212

8.8.1 Business Description 212

8.8.2 SWOT Analysis 213

8.8.3 Oncology Focus 219

8.9 Auron Healthcare GmbH 220

8.9.1 Business Description 220

8.10 Oncogenex Pharmaceuticals, Inc. 221

8.10.1 Business Description 221

8.11 Agennix AG 221

8.11.1 Business Description 221

8.12 GTx, Inc. 221

8.12.1 Business Description 221

8.13 GlaxoSmithKline plc. 222

8.13.1 Business Description 222

8.13.2 Financial Overview 223

8.13.3 SWOT Analysis 223

8.13.4 Oncology Focus 229

9 M&A Analysis 231

9.1 Key Highlights 231

9.2 Key Deals' Analysis 232

9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 232

9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 232

9.2.3 Tolmar Holding Acquires QLT USA from QLT 233

9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 233

9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 233

9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 233

9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 233

9.2.8 GPC Biotech Merges with Agennix 233

9.2.9 Eli Lilly Acquires ImClone 234

9.2.10 BBM Holdings Acquires YM BioSciences 234

9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 234

9.3 M&A Deals by Geography 235

9.4 M&A Deals by Deal Size 235

10 Appendix 236

10.1 Market Definitions 236

10.2 Abbreviations 236

10.3 Research Methodology 238

10.3.1 Coverage 238

10.3.2 Secondary Research 239

10.3.3 Forecasting 239

10.3.4 Primary Research 242

10.3.5 Expert Panel validation 242

10.3.6 Contact Us 242

10.3.7 Disclaimer 242

10.3.8 Sources 2431.1 List of Tables

Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 12

Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 14

Table 3: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2001–2009 21

Table 4: Prostate Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2001–2009 22

Table 5: Prostate Cancer Therapeutics Market, BRIC, Patient Volume, 2001–2009 23

Table 6: Prostate Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2001–2009 24

Table 7: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2009–2020 26

Table 8: Prostate Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2009–2020 27

Table 9: Prostate Cancer Therapeutics Market, BRIC, Patient Volume (absolute), 2009–2020 28

Table 10: Prostate Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2009–2020 29

Table 11: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001-2009 31

Table 12: Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001-2009 32

Table 13: Prostate Cancer Therapeutics Market, Brazil, Patient Volume ('000s), 2001-2009 33

Table 14: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2001-2009 34

Table 15: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2009-2020 38

Table 16: Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2009-2020 39

Table 17: Prostate Cancer, Brazil, Patient Volume ('000s), 2009-2020 40

Table 18: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2009-2020 41

Table 19: Prostate Cancer, Russia, Sales Value ($m), 2001-2009 44

Table 20: Prostate Cancer, Russia, Annual Cost of Therapy ($), 2001-2009 45

Table 21: Prostate Cancer, Russia, Patient Volume (Thousands), 2001-2009 46

Table 22: Prostate Cancer, Russia, Treatment Usage Patterns, 2001-2009 47

Table 23: Prostate Cancer, Russia, Sales Value ($m), 2009-2020 51

Table 24: Prostate Cancer, Russia, Annual Cost of Therapy ($), 2009-2020 52

Table 25: Prostate Cancer, Russia, Patient Volume (Thousands), 2009-2020 53

Table 26: Prostate Cancer, Russia, Treatment Usage Patterns, 2009-2020 54

Table 27: Prostate Cancer, India, Sales Value ($m), 2001-2009 57

Table 28: Prostate Cancer, India, Annual Cost of Therapy ($), 2001-2009 58

Table 29: Prostate Cancer, India, Patient Volume (Thousands), 2001-2009 59

Table 30: Prostate Cancer, India, Treatment Usage Patterns, 2001-2009 60

Table 31: Prostate Cancer, India, Sales Value ($m), 2009-2020 64

Table 32: Prostate Cancer, India, Annual Cost of Therapy ($), 2009-2020 65

Table 33: Prostate Cancer, India, Patient Volume (Thousands), 2009-2020 66

Table 34: Prostate Cancer, India, Treatment Usage Patterns, 2009-2020 67

Table 35: Prostate Cancer, China, Sales Value ($m), 2001-2009 70

Table 36: Prostate Cancer, China, Annual Cost of Therapy ($), 2001-2009 71

Table 37: Prostate Cancer, China, Patient Volume (Thousands), 2001-2009 72

Table 38: Prostate Cancer, China, Treatment Usage Patterns, 2001-2009 73

Table 39: Prostate Cancer, China, Sales Value ($m), 2009-2020 77

Table 40: Prostate Cancer, China, Annual Cost of Therapy ($), 2009-2020 78

Table 41: Prostate Cancer, China, Patient Volume (Thousands), 2009-2020 79

Table 42: Prostate Cancer, China, Treatment Usage Patterns, 2009-2020 80

Table 43: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 84

Table 44: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 85

Table 45: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 86

Table 46: Prostate Cancer, BRIC, Benchmarking Major Marketed Products, 2010 89

Table 47: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 94

Table 48: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 99

Table 49: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 100

Table 50: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 101

Table 51: Prostate Cancer, Global, Lupron, Efficacy End Point for Three Products 103

Table 52: Prostate Cancer, Global, Lupron, Incidence of Adverse Effects, 2010 104

Table 53: Prostate Cancer, Global, Licensing Agreements, 2009-2010 127

Table 54: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 129

Table 55: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 129

Table 56: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 143

Table 57: Prostate Cancer, Global, Phase I Pipeline, August 2010 145

Table 58: Prostate Cancer, Global, Phase II Pipeline, August 2010 147

Table 59: Prostate Cancer, Global, Phase III Pipeline, August 2010 154

Table 60: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 163

Table 61: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 164

Table 62: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 219

Table 63: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 220

Table 64: Prostate Cancer, Global, M&A Deals by Geography, 2010 2311.2

List of Figures

Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 20

Figure 2: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2001–2009 21

Figure 3: Prostate Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2001–2009 22

Figure 4: Prostate Cancer Therapeutics Market, BRIC, Patient Volume, 2001–2009 23

Figure 5: Prostate Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2001–2009 24

Figure 6: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2009–2020 26

Figure 7: Prostate Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2009–2020 27

Figure 8: Prostate Cancer Therapeutics Market, BRIC, Patient Volume (absolute), 2009–2020 28

Figure 9: Prostate Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2009–2020 29

Figure 10: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001-2009 31

Figure 11: Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001-2009 32

Figure 12: Prostate Cancer Therapeutics Market, Brazil, Patient Volume ('000s), 2001-2009 33

Figure 13: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2001-2009 34

Figure 14: Prostate Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2009 36

Figure 15: Prostate Cancer Therapeutics Market, Brazil, Historical Events Impact on the Market, 2010 37

Figure 16: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2009-2020 38

Figure 17: Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2009-2020 39

Figure 18: Prostate Cancer Therapeutics Market, Brazil, Patient Volume ('000s), 2009-2020 40

Figure 19: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2009-2020 41

Figure 20: Prostate Cancer Therapeutics Market, Brazil, Future Events Expected to Impact the Market, 2010 43

Figure 21: Prostate Cancer, Russia, Sales Value ($m), 2001-2009 44

Figure 22: Prostate Cancer, Russia, Annual Cost of Therapy ($), 2001-2009 45

Figure 23: Prostate Cancer, Russia, Patient Volume (Thousands), 2001-2009 46

Figure 24: Prostate Cancer, Russia, Treatment Usage Patterns, 2001-2009 47

Figure 25: Prostate Cancer, Russia, Market Drivers and Restraints, 2009 49

Figure 26: Prostate Cancer, Russia, Historical Events Impact on the Market, 2010 50

Figure 27: Prostate Cancer, Russia , Sales Value ($m), 2009-2020 51

Figure 28: Prostate Cancer, Russia , Annual Cost of Therapy ($), 2009-2020 52

Figure 29: Prostate Cancer, Russia , Patient Volume (Thousands), 2009-2020 53

Figure 30: Prostate Cancer, Russia, Treatment Usage Patterns, 2009-2020 54

Figure 31: Prostate Cancer, Russia, Future Events Expected to Impact the Market, 2010 56

Figure 32: Prostate Cancer, India, Sales Value ($m), 2001-2009 57

Figure 33: Prostate Cancer, India, Annual Cost of Therapy ($), 2001-2009 58

Figure 34: Prostate Cancer, India, Patient Volume (Thousands), 2001-2009 59

Figure 35: Prostate Cancer, India, Treatment Usage Patterns, 2001-2009 60

Figure 36: Prostate Cancer, India, Market Drivers and Restraints, 2009 62

Figure 37: Prostate Cancer, India, Historical Events and Their Impact on the Market, 2010 63

Figure 38: Prostate Cancer, India, Sales Value ($m), 2009-2020 64

Figure 39: Prostate Cancer, India, Annual Cost of Therapy ($), 2009-2020 65

Figure 40: Prostate Cancer, India, Patient Volume (Thousands), 2009-2020 66

Figure 41: Prostate Cancer, India, Treatment Usage Patterns, 2009-2020 67

Figure 42: Prostate Cancer, India, Future Events Expected to Affect the Market, 2010 69

Figure 43: Prostate Cancer, China, Sales Value ($m), 2001-2009 70

Figure 44: Prostate Cancer, China, Annual Cost of Therapy ($), 2001-2009 71

Figure 45: Prostate Cancer, China, Patient Volume (Thousands), 2001-2009 72

Figure 46: Prostate Cancer, China, Treatment Usage Patterns, 2001-2009 73

Figure 47: Prostate Cancer, China, Market Drivers and Restraints, 2009 75

Figure 48: Prostate Cancer, China, Historical Events and Their Impact on the Market, 2010 76

Figure 49: Prostate Cancer, China, Sales Value ($m), 2009-2020 77

Figure 50 Prostate Cancer, China, Annual Cost of Therapy ($), 2009-2020 78

Figure 51: Prostate Cancer, China, Patient Volume (Thousands), 2009-2020 79

Figure 52: Prostate Cancer, China, Treatment Usage Patterns, 2009-2020 80

Figure 53: Prostate Cancer, China, Future Events Expected to Impact the Market, 2010 82

Figure 54: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 87

Figure 55: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 88

Figure 56: Prostate Cancer, Global, Taxotere, Chemical Structure 90

Figure 57: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 92

Figure 58: Prostate Cancer, Global, Casodex, Chemical Structure 93

Figure 59: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010 97

Figure 60: Prostate Cancer, Global, Zoladex, Chemical Structure 98

Figure 61: Prostate Cancer, Global, Eligard , Chemical Structure 99

Figure 62: Prostate Cancer, Global, Lupron, Chemical Structure 102

Figure 63: Prostate Cancer, Global, Firmagon, Chemical Structure 106

Figure 64: Prostate Cancer, Global, Novatrone, Chemical Structure 108

Figure 65: Prostate Cancer, Global, Emcyt, Chemical Structure 110

Figure 66: Prostate Cancer, Global, Trelstar, Chemical Structure 111

Figure 67: Prostate Cancer, Global, Eulexin, Chemical Structure 112

Figure 68: Prostate Cancer, Global, Delestrogen, Chemical Structure 114

Figure 69: Prostate Cancer, Global, Gynodiol, Chemical Structure 115

Figure 70: Prostate Cancer, Global, Estrace, Chemical Structure 116

Figure 71: Prostate Cancer, Global, Tace, Chemical Structure 117

Figure 72: Prostate Cancer, Global, Nilandrone, Chemical Structure 118

Figure 73: Prostate Cancer, Global, Premarin, Chemical Structure 119

Figure 74: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 120

Figure 75: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 121

Figure 76: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 122

Figure 77: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 123

Figure 78: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 124

Figure 79: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 125

Figure 80: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 128

Figure 81: Prostate Cancer, Global, Aflibercept, Chemical Structure 133

Figure 82: Prostate Cancer, Global, Abiraterone, Chemical Structure 136

Figure 83: Prostate Cancer, Global, Zibotentan, Chemical Structure 138

Figure 84: Prostate Cancer, Global, MDV3100, Chemical Structure 141

Figure 85: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 157

Figure 86: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 158

Figure 87: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 158

Figure 88: Prostate Cancer, BRIC, Prostate Cancer, Opportunity and Unmet Need, 2010 159

Figure 89: Prostate Cancer, BRIC, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 162

Figure 90: Prostate Cancer, BRIC, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 162

Figure 91: Prostate Cancer, Global, Key Events Impacting the Future Market 165

Figure 92: Prostate Cancer, BRIC, Implications for Future Market Competition, 2010 166

Figure 93: Prostate Cancer, Global, Future Players in the Market, 2010 168

Figure 94: Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 170

Figure 95: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 171

Figure 96: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 172

Figure 97: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 177

Figure 98: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 179

Figure 99: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 185

Figure 100: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 186

Figure 101: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 187

Figure 102: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 188

Figure 103: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 192

Figure 104: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 193

Figure 105: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 193

Figure 106: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 194

Figure 107: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 195

Figure 108: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 200

Figure 109: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 201

Figure 110: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 203

Figure 111: Prostate Cancer, Global, Takeda Pharmaceuticals, SWOT Analysis 2010 206

Figure 112: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 208

Figure 113: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 213

Figure 114: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 220

Figure 115: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 223

Figure 116: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 229

Figure 117: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 230

Figure 118: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 235

Figure 119: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 235

Figure 120: GlobalData Market Forecasting Model 241

Companies mentioned

Sanofi-aventis

Pfizer Inc.

AstraZeneca

Bristol-Myers Squibb

Medivation

Takeda Pharmaceuticals

Dendreon Corporation

Johnson and Johnson

Auron Healthcare GmbH

Oncogenex Pharmaceuticals, Inc.

Agennix AG

GTx, Inc.

GlaxoSmithKline plc.

To order this report:

Drug and Medication Industry: Prostate Cancer - BRIC Drug Forecasts and Treatment Analysis to 2020

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com